Mesoblast pummelled as Novartis exits COVID deal
pharmaphorum
DECEMBER 14, 2021
In COVID-19, the drug was being tested in patients with acute respiratory distress (ARDS), which like GvHD is caused by over-stimulation of inflammatory cytokines, which causes the immune system to attack the patient’s own body. It has made cumulative loses of almost $650 million since being founded in 2004.
Let's personalize your content